 PLYMOUTH MEETING, Pa., Oct. 12, 2021 PRNewswire -- INOVIO NASDAQ:INO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800. 